BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34495433)

  • 1. Assessment of early metabolic progression in melanoma patients under immunotherapy: an
    Sachpekidis C; Kopp-Schneider A; Hassel JC; Dimitrakopoulou-Strauss A
    EJNMMI Res; 2021 Sep; 11(1):89. PubMed ID: 34495433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of [
    Sachpekidis C; Weru V; Kopp-Schneider A; Hassel JC; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2699-2714. PubMed ID: 37099131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interim [
    Sachpekidis C; Kopp-Schneider A; Pan L; Papamichail D; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1932-1943. PubMed ID: 33336264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value and accuracy of [
    Ayati N; Jamshidi-Araghi Z; Hoellwerth M; Schweighofer-Zwink G; Hitzl W; Koelblinger P; Pirich C; Beheshti M
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2715-2726. PubMed ID: 37140669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can physiologic colonic [
    Sachpekidis C; Stein-Thoeringer CK; Kopp-Schneider A; Weru V; Dimitrakopoulou-Strauss A; Hassel JC
    Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3709-3722. PubMed ID: 37452874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of interim
    Sachpekidis C; Anwar H; Winkler J; Kopp-Schneider A; Larribere L; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1289-1296. PubMed ID: 29478079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study.
    Sachpekidis C; Larribere L; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A; Hassel JC
    Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):386-96. PubMed ID: 25359635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing immune organs on
    Prigent K; Lasnon C; Ezine E; Janson M; Coudrais N; Joly E; Césaire L; Stefan A; Depontville M; Aide N
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2573-2585. PubMed ID: 33432374
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Ito K; Teng R; Schöder H; Humm JL; Ni A; Michaud L; Nakajima R; Yamashita R; Wolchok JD; Weber WA
    J Nucl Med; 2019 Mar; 60(3):335-341. PubMed ID: 30413661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective Assessment of Fluorine-18-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography (FDG-PET/CT) for Early Identification of Checkpoint-Inhibitor-Induced Pseudoprogression.
    Homburg S; Christensen CB; Pedersen M; Sørensen SG; Donia M; Svane IM; Hendel HW; Ellebaek E
    Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET-CT.
    Dimitrakopoulou-Strauss A
    Cancer Immunol Immunother; 2019 May; 68(5):813-822. PubMed ID: 30123922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can benign lymphoid tissue changes in
    Sachpekidis C; Larribère L; Kopp-Schneider A; Hassel JC; Dimitrakopoulou-Strauss A
    Cancer Immunol Immunother; 2019 Feb; 68(2):297-303. PubMed ID: 30478475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.
    Iravani A; Osman MM; Weppler AM; Wallace R; Galligan A; Lasocki A; Hunter MO; Akhurst T; Hofman MS; Lau PKH; Kee D; Au-Yeung G; Sandhu S; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2776-2786. PubMed ID: 32338306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy.
    Nakamoto R; Zaba LC; Rosenberg J; Reddy SA; Nobashi TW; Davidzon G; Aparici CM; Nguyen J; Moradi F; Iagaru A; Franc BL
    Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2787-2795. PubMed ID: 32296882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive
    Schwenck J; Schörg B; Fiz F; Sonanini D; Forschner A; Eigentler T; Weide B; Martella M; Gonzalez-Menendez I; Campi C; Sambuceti G; Seith F; Quintanilla-Martinez L; Garbe C; Pfannenberg C; Röcken M; la Fougere C; Pichler BJ; Kneilling M
    Theranostics; 2020; 10(2):925-937. PubMed ID: 31903160
    [No Abstract]   [Full Text] [Related]  

  • 16. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using
    Kitajima K; Watabe T; Nakajo M; Ishibashi M; Daisaki H; Soeda F; Tanemura A; Kanekura T; Yamazaki N; Ito K
    Jpn J Radiol; 2022 Jan; 40(1):75-85. PubMed ID: 34287739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response evaluation after immunotherapy in NSCLC: Early response assessment using FDG PET/CT.
    Park S; Lee Y; Kim TS; Kim SK; Han JY
    Medicine (Baltimore); 2020 Dec; 99(51):e23815. PubMed ID: 33371161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor response assessment on imaging following immunotherapy.
    Berz AM; Dromain C; Vietti-Violi N; Boughdad S; Duran R
    Front Oncol; 2022; 12():982983. PubMed ID: 36387133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive Value of Baseline FDG-PET/CT for the Durable Response to Immune Checkpoint Inhibition in NSCLC Patients Using the Morphological and Metabolic Features of Primary Tumors.
    Kudura K; Ritz N; Kutzker T; Hoffmann MHK; Templeton AJ; Foerster R; Kreissl MC; Antwi K
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse effects under immune checkpoint inhibitors on [18F]FDG PET/CT imaging.
    Sachpekidis C; Hassel JC; Dimitrakopoulou-Strauss A
    Q J Nucl Med Mol Imaging; 2022 Sep; 66(3):245-254. PubMed ID: 35612369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.